Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.63 |
| ▸ | THPO | P40225 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | BMP1 | P13497 | 2/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 5/20 | 0.35 |
| ▸ | MMP9 | P14780 | 4/20 | 0.34 |
| ▸ | MMP2 | P08253 | 2/20 | 0.34 |
| ▸ | MMP8 | P22894 | 2/20 | 0.34 |
| ▸ | MMP3 | P08254 | 2/20 | 0.34 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13299209 | 1.00 | KDM4E (0.63) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL10045860 | 1.00 | KDM4E (0.63) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL20328839 | 0.85 | KDM4E (0.52) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL4990551 | 0.84 | BMP1 (0.45) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL17623527 | 0.83 | KDM4E (0.48) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL4704123 | 0.83 | BMP1 (0.47) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL4988312 | 0.83 | BMP1 (0.44) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL12354387 | 0.81 | KDM4E (0.61) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL928644 | 0.81 | KDM4E (0.61) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL27447128 | 0.81 | KDM4E (0.61) | KDM4EMAPTTHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4598516-A2 | MITOCHONDRIA-TARGETED N-ACETYLCYSTEINE AND ANALOGS | The Medical College of Wisconsin, Inc. (US) | 2025-08-13 | — | — | EP | claimed |
| WO-2024077062-A2 | MITOCHONDRIA-TARGETED N-ACETYLCYSTEINE AND ANALOGS | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2024-04-11 | — | — | WO | claimed |
| US-20250346938-A1 | ATP-DEPENDENT C-TERMINAL MODIFICATION OF POLYPEPTIDES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4598516-A2 | MITOCHONDRIA-TARGETED N-ACETYLCYSTEINE AND ANALOGS | The Medical College of Wisconsin, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2024205472-A1 | COMPOSITION FOR USE IN PREVENTION AND/OR TREATMENT OF HUMAN TRANSTHYRETIN AMYLOIDOSIS | OLOFSSON ANDERS (SE) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024077062-A2 | MITOCHONDRIA-TARGETED N-ACETYLCYSTEINE AND ANALOGS | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| US-11045523-B2 | Formulation of growth hormone albumin-binder conjugate | NOVO NORDISK HEALTHCARE AG (CH) | 2021-06-29 | — | — | US | disclosed |
| US-10869846-B2 | N-acetylcysteine amide (NAC amide) in the treatment of diseases and conditions associated with oxidative stress | SENTIENT LIFESCIENCES, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190203213-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2019-07-04 | — | — | US | disclosed |
| US-20190111009-A1 | N-ACETYLCYSTEINE AMIDE (NAC AMIDE) IN THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH OXIDATIVE STRESS | SENTIENT LIFESCIENCES, INC. | 2019-04-18 | — | — | US | disclosed |
| US-20170239362-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTHCARE AG (CH) | 2017-08-24 | — | — | US | disclosed |
| US-20120309944-A1 | Growth Hormones With Prolonged In-Vivo Efficacy | NOVO NORDISK HEALTH CARE AG (CH) | 2012-12-06 | — | — | US | disclosed |
| US-20120289682-A1 | Tyrosine Bioconjugation through Aqueous Ene-Like Reactions | THE SCRIPPS RESEARCH INSTITUTE | 2012-11-15 | — | — | US | disclosed |
| WO-2011079315-A1 | TYROSINE BIOCONJUGATION THROUGH AQUEOUS ENE-LIKE REACTIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20100137441-A1 | N-ACETYLCYSTEINE AMIDE (NAC AMIDE) FOR THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH OXIDATIVE STRESS | SENTIENT LIFESCIENCES, INC. | 2010-06-03 | — | — | US | disclosed |
| US-20100137441-A1 | N-ACETYLCYSTEINE AMIDE (NAC AMIDE) FOR THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH OXIDATIVE STRESS | SENTIENT LIFESCIENCES, INC. | 2010-06-03 | — | — | US | disclosed |
| US-20100120920-A1 | N-ACETYLCYSTEINE AMIDE (NAC AMIDE) FOR THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH OXIDATIVE STRESS | SENTIENT LIFESCIENCES, INC. | 2010-05-13 | — | — | US | disclosed |
| US-20100120920-A1 | N-ACETYLCYSTEINE AMIDE (NAC AMIDE) FOR THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH OXIDATIVE STRESS | SENTIENT LIFESCIENCES, INC. | 2010-05-13 | — | — | US | disclosed |
| US-20090234011-A1 | N-ACETYLCYSTEINE AMIDE (NAC AMIDE) FOR THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH OXIDATIVE STRESS | DAVID PHARMACEUTICALS | 2009-09-17 | — | — | US | disclosed |
| US-20090234011-A1 | N-ACETYLCYSTEINE AMIDE (NAC AMIDE) FOR THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH OXIDATIVE STRESS | DAVID PHARMACEUTICALS | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309944-A1 | Growth Hormones With Prolonged In-Vivo Efficacy | GHRHR, SHBG, GHSR | KDM4E 3892/4885MAPT 4551/4885THRB 69/4885 |
| US-20100120920-A1 | N-ACETYLCYSTEINE AMIDE (NAC AMIDE) FOR THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH OXIDATIVE STRESS | GCLC, NAT1, HHAT | KDM4E 4862/4885MAPT 1119/4885THRB 1897/4885 |
| US-11045523-B2 | Formulation of growth hormone albumin-binder conjugate | ALB, SHBG, SERPINA6 | KDM4E 3418/4885MAPT 691/4885THRB 187/4885 |
| US-20100137441-A1 | N-ACETYLCYSTEINE AMIDE (NAC AMIDE) FOR THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH OXIDATIVE STRESS | GCLC, NAT1, HHAT | KDM4E 4862/4885MAPT 1119/4885THRB 1897/4885 |
| US-20170239362-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | SHBG, GHRHR, GHITM | KDM4E 3808/4885MAPT 4489/4885THRB 75/4885 |
| US-10869846-B2 | N-acetylcysteine amide (NAC amide) in the treatment of diseases and conditions associated with oxidative stress | GCLC, NAT1, HHAT | KDM4E 4864/4885MAPT 1059/4885THRB 1957/4885 |
| US-20190203213-A1 | Growth Hormones with Prolonged In-Vivo Efficacy | SHBG, GHRHR, GHITM | KDM4E 3808/4885MAPT 4489/4885THRB 75/4885 |
| US-20120289682-A1 | Tyrosine Bioconjugation through Aqueous Ene-Like Reactions | TYR, DNPEP, TH | KDM4E 225/4885MAPT 1928/4885THRB 1322/4885 |
| US-20190111009-A1 | N-ACETYLCYSTEINE AMIDE (NAC AMIDE) IN THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH OXIDATIVE STRESS | GCLC, NAT1, HHAT | KDM4E 4864/4885MAPT 1059/4885THRB 1957/4885 |
| US-20090234011-A1 | N-ACETYLCYSTEINE AMIDE (NAC AMIDE) FOR THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH OXIDATIVE STRESS | GCLC, NAT1, HHAT | KDM4E 4862/4885MAPT 1119/4885THRB 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.